Regeneron Pharmaceuticals Inc. buy Wells Fargo & Company
Summary
This prediction ended on 03.08.25 with a price of €482.20. Massive losses of -51.42% were the result for the BUY prediction by Wells_Fargo___Compan. Wells_Fargo___Compan has a follow-up prediction for Regeneron Pharmaceuticals Inc. where he still thinks Regeneron Pharmaceuticals Inc. is a Buy. Dividends of €1.72 are taken into consideration when calculating the performance. Wells_Fargo___Compan has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 0.533% | 0.533% | 21.874% |
| iShares Core DAX® | -1.741% | 5.979% | 8.977% |
| iShares Nasdaq 100 | 2.815% | 11.827% | 38.406% |
| iShares Nikkei 225® | -0.109% | 11.692% | 46.680% |
| iShares S&P 500 | 0.966% | 7.616% | 28.141% |
Comments by Wells_Fargo___Compan for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
In the thread Trading Regeneron Pharmaceuticals Inc.
Current prediction by Wells_Fargo___Compan for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
30.04.25
30.04.26
24.04.26
Stopped prediction by Wells_Fargo___Compan for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
10.01.25
10.01.26
11.01.26
Regeneron Pharmaceuticals Inc.
23.09.24
23.09.25
24.09.25

